Narlumosbart Compared With Denosumab in Patients With Multiple Myeloma Bone Disease

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2024
The purpose of this study is to determine if narlumosbart is non-inferior to denosumab in the treatment of bone diseases from multiple myeloma (MM).
Epistemonikos ID: a5c21d457900fc96ddb40d038900fd9cf750a4ab
First added on: May 15, 2024